Publication details
Fondaparinux a jeho adekvátní použití v praxi
| Title in English | Fondaparinux and its appropriate use in practice |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://farmakoterapeutickarevue.cz/cs/fondaparinux-a-jeho-adekvatni-pouziti-v-praxi |
| Keywords | fondaparinux; monitoring; unlabeled indication; dosage; obesity; pregnancy |
| Description | Fondaparinux is a synthetic selective factor Xa inhibitor approved for the prevention and treatment of thromboembolism in adults. It is, however, most often mentioned in relation to heparin-induced thrombocytopenia as one of the therapeutic alternatives. It also plays a key role as a therapeutic alternative in heparin intolerant pregnant women. The aim of this paper is to review the most important pharmacological properties of fondaparinux and link them to daily practice, to provide information on monitoring the efficacy and safety of fondaparinux and to offer an overview of the available data for its dosing in selected populations. |